Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 40: 96-100, 1994;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jakob, G.
Right arrow Articles by Puschendorf, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jakob, G.
Right arrow Articles by Puschendorf, B.

Clinical Chemistry, Vol 40, 96-100, Copyright © 1994 by American Association for Clinical Chemistry

Clinical significance of urinary cyclic guanosine monophosphate in diagnosis of heart failure

G Jakob, J Mair, KP Vorderwinkler, G Judmaier, P Konig, H Zwierzina, M Pichler and B Puschendorf
Department of Medical Chemistry and Biochemistry, University of Innsbruck Medical School, Austria.

We measured concentrations of guanosine 3',5'-monophosphate (cGMP) in plasma and urine of healthy subjects and patients with congestive heart failure, renal impairment, neoplastic disease, and hepatic cirrhosis. There was no correlation between cGMP concentrations in urine and in plasma. In all patients except those with renal impairment, urinary cGMP concentrations were significantly higher than in healthy persons. Only patients with heart failure or renal impairment showed significantly increased plasma cGMP concentrations. In contrast, cGMP in urine does not relate to the clinically assessed severity of heart failure (New York Heart Association functional classes). Determination of cGMP in plasma results in higher sensitivity and specificity for diagnosing heart failure than measurement of cGMP in urine.


The following articles in journals at HighWire Press have cited this article:


Home page
 J Am Coll CardiolHome page
J. M. Hare, G. C. Nguyen, A. F. Massaro, J. M. Drazen, L. W. Stevenson, W. S. Colucci, J. C. Fang, W. Johnson, M. M. Givertz, and C. Lucas
Exhaled nitric oxide: a marker of pulmonary hemodynamics in heart failure
J. Am. Coll. Cardiol., September 18, 2002; 40(6): 1114 - 1119.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
S. L. Carrithers, S. L. Eber, L. R. Forte, and R. N. Greenberg
Increased urinary excretion of uroguanylin in patients with congestive heart failure
Am J Physiol Heart Circ Physiol, February 1, 2000; 278(2): H538 - H547.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
M. Bogdan, M. Humbert, J. Francoual, C. Claise, P. Duroux, G. Simonneau, and A. Lindenbaum
Urinary cGMP concentrations in severe primary pulmonary hypertension
Thorax, December 1, 1998; 53(12): 1059 - 1062.
[Abstract] [Full Text]

Home page
 CirculationHome page
J. Mair, B. Puschendorf, R. H. Boger, and S. M. Bode-Boger
Is Measurement of Cyclic Guanosine Monophosphate in Plasma or Urine Suitable for Assessing In Vivo Nitric Oxide Production? • Response
Circulation, March 31, 1998; 97(12): 1209 - 1210.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the American Association for Clinical Chemistry.